SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), announced its decision to advance prasinezumab-a potential anti-alpha-synuclein antibody-into Phase III clinical development for early-stage Parkinson's disease. The decision is based on findings from the Phase IIb PADOVA study, as well as ongoing open-label extensions (OLEs) of both the PADOVA and Phase II PASADENA trials.
The ongoing PASADENA and PADOVA open-label extension (OLE) studies are evaluating the long-term safety and efficacy of prasinezumab in more than 750 individuals with early-stage Parkinson's disease.
Roche's Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
